Werbung
Werbung

ATOS

ATOS logo

Atossa Therapeutics, Inc. Common Stock

0.65
USD
Gesponsert
-0.01
-1.07%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

0.64

-0.01
-1.08%

ATOS Ergebnisberichte

Positives Überraschungsverhältnis

ATOS übertreffen die 20 der letzten 31Schätzungen.

65%

Nächster Bericht

Datum des nächsten Berichts
23. März 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.06
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
-14.29%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
+20.00%

Atossa Therapeutics, Inc. Common Stock earnings per share and revenue

On 12. Nov. 2025, ATOS reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of -0.06 USD, resulting in a -2.94% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.74% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.06 USD, with revenue projected to reach -- USD, implying an decrease of -14.29% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06. Jan. 2026 For Q2 26
Estimate
-$0.10
Aktuell
$0.00
Überraschung
+100.00%
FAQ
For Q3 2025, Atossa Therapeutics, Inc. Common Stock reported EPS of -$0.07, missing estimates by -2.94%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.74%, changed from $0.83 before the earnings release to $0.81 the day after.
The next earning report is scheduled for 23. März 2026.
Based on 5 analysts, Atossa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung